207 related articles for article (PubMed ID: 35754475)
1. A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan.
Khan MAA; Hamid S; Khan SA; Sarfraz M; Babar ZU
Front Pharmacol; 2022; 13():891954. PubMed ID: 35754475
[No Abstract] [Full Text] [Related]
2. Assessment of the Current State of Pharmacovigilance System in Pakistan Using Indicator-Based Assessment Tool.
Khan MAA; Hamid S; Ur-Rehman T; Babar ZU
Front Pharmacol; 2021; 12():789103. PubMed ID: 35095498
[No Abstract] [Full Text] [Related]
3. Exploring the factors and barriers of healthcare professionals in tertiary care hospitals toward pharmacovigilance: a multicenter study from Khyber Pakhtunkhwa, Pakistan.
Sharif MJH; Farrukh MJ; Khan FU; Khan Q; Ahmed SS; Kousar R; Ahmad T; Abid SMA; Ashfaq M; Khan SA
Curr Med Res Opin; 2022 Apr; 38(4):595-605. PubMed ID: 35166143
[TBL] [Abstract][Full Text] [Related]
4. A qualitative exploration of knowledge, attitudes and practices of hospital pharmacists towards adverse drug reaction reporting system in Lahore, Pakistan.
Hussain R; Hassali MA; Hashmi F; Farooqui M
J Pharm Policy Pract; 2018; 11():16. PubMed ID: 30034811
[TBL] [Abstract][Full Text] [Related]
5. Physicians' Understanding and Practices of Pharmacovigilance: Qualitative Experience from A Lower Middle-Income Country.
Hussain R; Hassali MA; Ur Rehman A; Muneswarao J; Hashmi F
Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32218355
[TBL] [Abstract][Full Text] [Related]
6. A Qualitative Evaluation of Adverse Drug Reaction Reporting System in Pakistan: Findings from the Nurses' Perspective.
Hussain R; Hassali MA; Ur Rehman A; Muneswarao J; Atif M; Babar ZU
Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32349339
[TBL] [Abstract][Full Text] [Related]
7. Identifying priority medicines policy issues for Qatar: exploring perspectives and experiences of healthcare professionals through a qualitative study.
Zia N; Ibrahim MIM; Adheir F; Babar ZU
BMJ Open; 2021 Nov; 11(11):e054150. PubMed ID: 34819289
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study-study protocol.
Dweik RA; Yaya S; Stacey D; Kohen D
Springerplus; 2016; 5():213. PubMed ID: 27026907
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
10. Health-care Professionals' Knowledge and Perception of Adverse Drug Reaction Reporting and Pharmacovigilance in a Tertiary Care Teaching Hospital of Nepal.
Danekhu K; Shrestha S; Aryal S; Shankar PR
Hosp Pharm; 2021 Jun; 56(3):178-186. PubMed ID: 34024926
[No Abstract] [Full Text] [Related]
11. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
Inácio P; Cavaco A; Allan E; Airaksinen M
Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
[TBL] [Abstract][Full Text] [Related]
12. An Exploration of Knowledge, Attitude, and Practices of Physicians toward Pharmacovigilance at Tertiary Care Hospitals in Khyber-Pakhtunkhwa Province, Pakistan.
Sharif MJH; Murtaza G; Kharaba Z; Ibrahim NA; Ismail M; Mannan A; Buabeid M; Huang X; Khan SA; Hayat K
Am J Trop Med Hyg; 2021 Sep; 105(6):1624-1630. PubMed ID: 34491215
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates.
Güner MD; Ekmekci PE
J Drug Assess; 2019; 8(1):13-20. PubMed ID: 30729064
[No Abstract] [Full Text] [Related]
15. Exploring healthcare professionals' knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey.
Hussain R; Hassali MA; Hashmi F; Akram T
J Pharm Policy Pract; 2021 Jan; 14(1):5. PubMed ID: 33397478
[TBL] [Abstract][Full Text] [Related]
16. Thai stakeholders' awareness and perceptions of the patient adverse event reporting system for herbal medicines: a qualitative study.
Worakunphanich W; Suwankesawong W; Youngkong S; Thavorncharoensap M; Anderson C; Toh LS
Int J Clin Pharm; 2023 Apr; 45(2):491-501. PubMed ID: 36745312
[TBL] [Abstract][Full Text] [Related]
17. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements.
Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG
Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480
[TBL] [Abstract][Full Text] [Related]
18. Stakeholders' knowledge, attitudes and practices to pharmacovigilance and adverse drug reaction reporting in clinical trials: a mixed methods study.
Riordan DO; Kinane M; Walsh KA; Shiely F; Eustace J; Bermingham M
Eur J Clin Pharmacol; 2020 Oct; 76(10):1363-1372. PubMed ID: 32507924
[TBL] [Abstract][Full Text] [Related]
19. Knowledge, attitude, practice and barriers towards pharmacovigilance and adverse drug reactions reporting among healthcare professionals in Turkey: a systematic review.
Khan Z; Karatas Y; Martins MAP; Jamshed S; Rahman H
Curr Med Res Opin; 2022 Jan; 38(1):145-154. PubMed ID: 34694167
[TBL] [Abstract][Full Text] [Related]
20. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
Jarernsiripornkul N; Patsuree A; Krska J
Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
